I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Currently, in-stent restenosis (ISR) remains a problem in percutaneous coronary intervention as it is associated with a high rate of repeat revascularization.\[[@ref1]\] Previous study has demonstrated the efficacy of drug-eluting stent (DES) for the treatment of ISR.\[[@ref2]\] Nevertheless, with increased risk of late stent thrombosis (ST) due to incomplete endothelialization and inflammatory response, first-generation DES is restricted to longer-term dual antiplatelet therapy compared with bare-metal stent (BMS).\[[@ref3]\] Recent network meta-analysis indicates that new-generation DES is associated with significantly lower rates of ST as compared to BMS and first-generation DES, which makes it an appropriate choice for the treatment of ISR.\[[@ref4]\]

Drug-eluting balloon (DEB) is emerging as a potential alternative to the current treatment of ISR. It can deliver active drugs homogeneously to inhibit neointimal hyperplasia without remaining in the arteries permanently.\[[@ref5]\] Furthermore, in the updated European Society of Cardiology (ESC) guidelines, DEB receives a class I recommendation (level of evidence A) for both BMS-ISR and DES-ISR.\[[@ref6]\] Most available studies have only compared DEB to the first-generation DES but not the new-generation DES, which appears to be most widely adopted to increase the safety and efficacy of DES implantation.\[[@ref7]\]

Previous meta-analysis involving 1065 patients has demonstrated that DEB was associated with higher incidence of target lesion revascularization (TLR) and major adverse cardiovascular event (MACE) as compared to new-generation DES for the treatment of ISR.\[[@ref8]\] However, this study was limited by a small sample size. In the past few years, there have been several studies comparing DEB with new-generation DES in treating ISR, though most of them were observational studies without adequate evidences. The recently presented Drug-Eluting Balloon for In-Stent Restenosis (DARE) Trial at the Transcatheter Cardiovascular Therapeutics (TCT) annual conference has shown that treatment with SeQuent Please was noninferior to XIENCE in terms of 6-month minimal lumen diameter (MLD).\[[@ref9]\] Here, we performed a meta-analysis of all the currently available clinical trials to compare the safety and efficacy of DEB with those of new-generation DES in the treatment of ISR.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

This study was performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement\[[@ref10]\] and Meta-analysis of Observational Studies in Epidemiology checklist.\[[@ref11]\]

Search strategy {#sec2-1}
---------------

A comprehensive search of electronic databases including PubMed, EMBASE, and Cochrane Library up to November 2, 2017 was performed to identify pertinent articles comparing DEB to new-generation DES for the treatment of ISR. In addition, conference proceedings for the scientific sessions of the American College of Cardiology, American Heart Association, ESC, TCT, and EuroPCR were also searched. The following medical subject headings and search terms were used: "drug-eluting balloon", "drug-coated balloon", "paclitaxel-coated balloon", "paclitaxel-eluting balloon", "stent", "restenosis", and "in-stent restenosis". The references of the identified articles and relevant reviews were screened to include other potentially suitable trials. The authors of the original studies were not contacted for additional information.

Study selection {#sec2-2}
---------------

Studies satisfying the following criteria were eligible: (1) randomized controlled trials (RCTs) or observational studies regarding ISR; (2) compared DEB to new-generation DES directly; (3) follow-up lasted for at least 6 months; and (4) reported endpoint data of interest. The selection was conducted by scanning of titles or abstracts, and full-text reviews were performed for further analysis. When several reports overlapped with each other, we selected the largest and the latest one. The studies were reviewed by two independent investigators to determine whether or not they met the inclusion criteria, and any disagreement was resolved by consensus.

Data extraction {#sec2-3}
---------------

The following data were extracted independently by two investigators using a standardized form from each study: study characteristics, patient characteristics, and outcomes (angiographic and clinical outcomes). Differences in assessments were resolved by discussing with a third investigator. The primary endpoint was TLR at the longest follow-up. The most similar endpoint, i.e., target vessel revascularization (TVR), was chosen in case TLR was not reported. All-cause death, cardiac death, MACE, myocardial infarction (MI), ST, late lumen loss (LLL), and MLD were the secondary outcomes. In addition, MACE was defined variable in each study.

Quality assessment {#sec2-4}
------------------

The quality of RCTs and observational studies was assessed. The RCTs were evaluated according to the following methodological criteria recommended by the Cochrane Collaboration: sequence generation, concealment of allocation, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias.\[[@ref12]\] The observational studies were evaluated using the Newcastle-Ottawa Scale criteria.\[[@ref13]\]

Statistical analysis {#sec2-5}
--------------------

Dichotomous data and continuous variables were presented as risk ratios (*RR*s) and mean differences (MDs) with 95% confidence intervals (*CI*s), respectively. For *RR*s, the Mantel-Haenszel random-effects model was used, and the overall MD was estimated using the inverse variance random-effects model. Potential heterogeneity among studies was quantified with *I*^2^ and *I*^2^ \>50% was defined as statistical heterogeneity. Furthermore, we used funnel plots to assess the potential publication bias. All statistical analyses were performed with Review Manager 5.1 (Cochrane Center, Denmark).

Subgroup analysis was carried out to explore the sources of heterogeneity (RCTs and observational studies). Another method to examine whether the *RR*s/MDs were significantly changed was to remove the studies according to the following variables: (1) lesions were restricted to BMS-ISR or DES-ISR; (2) DEB was restricted to SeQuent Please; (3) DES was restricted to everolimus-eluting stent (EES); and (4) excluding recurrent ISR. Sensitivity analysis was also performed to demonstrate the robustness of the results by omitting one study in each turn. All *P* values were two-sided, and results were considered statistically significant when the value of *P* \< 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Eligible studies {#sec2-6}
----------------

After a comprehensive search according to the inclusion criteria, 1643 potentially relevant articles were identified in the initial analysis. Among them, 26 articles were chosen for complete review. Finally, 13 studies (including 5 RCTs and 8 observational studies) involving 2743 patients were included in the present meta-analysis \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref9][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25]\] Note that, the 3-year outcomes of RIBS IV trial were reported in TCT annual conference, with data not yet available, so the related study with 1-year clinical follow-up data was enrolled.\[[@ref15]\]

![Flowchart of identification of eligible studies in this study. DEB: Drug-eluting balloon; DES: Drug-eluting stent.](CMJ-131-600-g001){#F1}

The patient characteristics and methodology of the included studies are briefly depicted in [Table 1](#T1){ref-type="table"}. The baseline and procedural characteristics of patients are presented in [Supplementary Table 1](#T2){ref-type="table"}. Among the 13 trials, the adopted DEBs were varied, including SeQuent Please, In. PACT Falcon, and other paclitaxel-eluting balloons. Regarding the devices in control groups, EES was used exclusively in seven trials.\[[@ref9][@ref14][@ref15][@ref16][@ref17][@ref21][@ref25]\] Overall, two trials enrolled patients with recurrent ISR,\[[@ref20][@ref21]\] three trials enrolled patients with BMS-ISR,\[[@ref14][@ref16][@ref25]\] and five trials enrolled patients with DES-ISR\[[@ref15][@ref17][@ref18][@ref19][@ref20]\] exclusively. The clinical follow-up period ranged from 12 to 36 months and the duration of angiographic follow-up varied from 6 to 12 months. Quality assessment results are described in Supplementary Tables [2](#T3){ref-type="table"} and [3](#T4){ref-type="table"}. The assessment of the funnel plot was performed in terms of TLR and no publication bias was found \[Supplementary Figure 1\].

###### 

Patient characteristics and methodology of the included studies

  Studies                               Years   Study period   Lesion characteristics   Comparison                                    Number of patients   Angiographic follow-up (months)   Clinical follow-up (months)   Definition of MACE
  ------------------------------------- ------- -------------- ------------------------ --------------------------------------------- -------------------- --------------------------------- ----------------------------- -------------------------------------
  Adriaenssens *et al*.\[[@ref14]\]     2014    2009--2011     BMS ISR                  SeQuent Please versus EES                     50                   9                                 12                            NA
  Alfonso *et al*.\[[@ref15]\]          2015    2010--2013     DES ISR                  SeQuent Please versus EES                     309                  6--10                             12                            Cardiac death, MI, or TLR
  Alfonso *et al*.\[[@ref14][@ref26]    2016    2010--2012     BMS ISR                  SeQuent Please versus EES                     189                  6--9                              36                            Death, MI, or TVR
  Almalla *et al*.\[[@ref17][@ref27]    2015    2006--2011     DES ISR                  DEB versus EES                                86                   NA                                36                            Death, MI, or TLR
  Basavarajaiah *et al*.\[[@ref18]\]    2016    2009--2011     DES ISR                  In.PACT Falcon versus 2^nd^ DES               247                  NA                                24                            Cardiac death, TVMI, or TVR
  Henriques and Baan\[[@ref9]\]         2017    2010--2015     ISR                      SeQuent Please versus EES                     278                  6                                 12                            Death, TVMI, or TVR
  Kang *et al*.\[[@ref19]\]             2016    2007--2014     DES ISR                  SeQuent Please versus 2^nd^ DES               238                  NA                                24                            Cardiac death, MI, ST, or TVR
  Kawamoto *et al*.\[[@ref20]\]         2015    2008--2013     Recurrent DES ISR        In.PACT Falcon/Pantera Lux versus 2^nd^ DES   133                  NA                                24                            Death, MI, or TLR
  Kubo *et al*.\[[@ref21]\]             2015    2008--2012     Recurrent DEB ISR        SeQuent Please versus EES                     89                   6--8                              24                            NA
  Lee *et al*.\[[@ref22]\]              2017    2008--2014     ISR                      DEB versus 2^nd^ DES                          628                  NA                                12                            Death, MI, or revascularization
  Marquis-Gravel *et al*.\[[@ref23]\]   2013    2009--2012     ISR                      DEB versus 2^nd^ DES                          202                  NA                                16                            Death, MI, or clinically-driven TLR
  Naganuma *et al*.\[[@ref24]\]         2016    2007--2012     ISR with bifurcation     In.PACT Falcon versus 2^nd^ DES               158                  NA                                24                            Cardiac death, MI, or TVR
  Pleva *et al*.\[[@ref25]\]            2016    2012--2014     BMS ISR                  SeQuent Please versus EES                     136                  12                                12                            Cardiac death, MI, or TVR

BMS: Bare-metal stent; DEB: Drug-eluting balloon; DES: Drug-eluting stent; EES: Everolimus-eluting stent; ISR: In-stent restenosis; MACE: Major adverse cardiac event; MI: Myocardial infarction; NA: Not applicable; ST: Stent thrombosis; TLR: Target lesion revascularization; TVMI: Target vessel myocardial infarction; TVR: Target vessel revascularization.

###### 

Baseline and procedural characteristics of patients of the included studies

  Studies                           Age (years)              Male (%)         Smoking (%)        Diabetes (%)                Hypertension (%)          Dyslipidemia (%)   
  --------------------------------- ------------------------ ---------------- ------------------ --------------------------- ------------------------- ------------------ -------------------
  Adriaenssens *et al*. in 2014     67.6/64.2                72/100           20.8/12            24/4                        64/60                     96/96              
  Alfonso *et al*. in 2015          66/66                    82/84            58/56              49/43                       71/78                     71/78              
  Alfonso *et al*. in 2016          67/64                    86/87            59/75              32/20                       72/72                     73/66              
  Almalla *et al*. in 2015          69.6/67.7                82/70            30.4/52.5          39.1/35                     80.4/85                   NA                 
  Basavarajaiah *et al*. in 2016    66.8/65.7                90.1/86.1        8.6/7.2            46.9/33.1                   70.4/71.1                 72.8/76.5          
  Henriques *et al*. in 2017        66/65                    72/84            17/13              31/33                       64/67                     59/60              
  Kang *et al*. in 2016             63.1/59.5                68.7/64.3        46.7/46.4          44.0/28.6                   72.5/69.6                 90.7/82.1          
  Kawamoto *et al*. in 2015         67.2/64.9                87.7/92.6        9.2/13.2           43.1/41.2                   78.5/79.4                 78.5/79.4          
  Kubo *et al*. in 2015             69.7/71.3                86.5/78.8        75.7/69.2          48.6/50.0                   81.1/78.8                 64.9/71.2          
  Lee *et al*. in 2017              66.2/65.3                63.9/70.4        16.9/23.7          53.0/45.7                   75.3/70.2                 53.0/49.6          
  Marquis-Gravel *et al*. in 2013   NA                       NA               NA                 NA                          NA                        NA                 
  Naganuma *et al*. in 2016         67.2/65.2                91.8/87.1        6.8/7.1            39.7/37.6                   71.2/71.8                 74/81.2            
  Pleva *et al*. in 2016            65.6/65.5                63.2/67.7        45.6/42.7          25.0/26.5                   NA                        NA                 
                                                                                                                                                                          
  **Studies**                       **Lesion length (mm)**   **Pre-DS (%)**   **Pre-MLD (mm)**   **DEB/DES diameter (mm)**   **DEB/DES length (mm)**   **Post-DS (%)**    **Post-MLD (mm)**
                                                                                                                                                                          
  Adriaenssens *et al*. in 2014     NA                       67.7/79.4        0.98/0.57          3.2/3                       23.3/26                   26.6/25.9          2.13/2.12
  Alfonso *et al*. in 2015          10.4/10.7                69/72            0.79/0.75          NA                          19/19                     18/13              2.10/2.22
  Alfonso *et al*. in 2016          13.7/13.8                61/65            1.02/0.93          NA                          20/23                     19/11              2.16/2.38
  Almalla *et al*. in 2015          9.0/12.3                 NA               0.57/0.51          2.96/2.84                   21.2/20.5                 NA                 2.42/2.50
  Basavarajaiah *et al*. in 2016    NA                       NA               NA                 3/3.2                       35.4/19.8                 NA                 NA
  Henriques *et al*. in 2017        NA                       69.7/69.3        0.77/0.79          3.3/2.9                     22.4/22.1                 29.9/26.2          1.72/1.84
  Kang *et al*. in 2016             19.5/21.3                71.7/74.6        0.8/0.8            3/3.2                       21.7/21.9                 20.6/13.6          2.2/2.7
  Kawamoto *et al*. in 2015         18.7/16.1                74.8/81.2        0.74/0.66          3.14/3.20                   33.7/25.0                 18.2/13.8          2.34/2.65
  Kubo *et al*. in 2015             16.7/15.7                67.0/72.2        0.96/0.80          2.98/2.90                   24.1/19.4                 31.8/16.2          2.02/2.56
  Lee *et al*. in 2017              NA                       NA               NA                 NA                          NA                        NA                 NA
  Marquis-Gravel *et al*. in 2013   NA                       NA               NA                 NA                          NA                        NA                 NA
  Naganuma *et al*. in 2016         NA                       NA               NA                 3.1/3.1                     37.3/23.5                 NA                 NA
  Pleva *et al*. in 2016            NA                       71.8/78.0        2.64/2.66          3.32/3.31                   22.5/28.5                 19.5/16.3          2.18/2.51

The data of the DEB group are on the left side of the oblique line, while the data of the new-generation group are on the right side of the oblique line. DEB: Drug-eluting balloon; DES: Drug-eluting stent; DS: Diameter stenosis; MLD: Minimal lumen diameter; NA: Not applicable.

###### 

Assessment of randomized controlled trials

  Study                           Sequence generation   Concealment of allocation   Blinding of participants, personnel and outcome assessors   Incomplete outcome data addressed   Free of selective reporting   Free of other bias
  ------------------------------- --------------------- --------------------------- ----------------------------------------------------------- ----------------------------------- ----------------------------- --------------------
  Adriaenssens *et al*. in 2014   Low                   Low                         High                                                        High                                Low                           Low
  Alfonso *et al*. in 2015        Low                   Low                         Moderate                                                    Low                                 Low                           Low
  Alfonso *et al*. in 2016        Low                   Low                         Moderate                                                    Low                                 Low                           Low
  Henriques *et al*. in 2017      NA                    NA                          NA                                                          NA                                  NA                            NA
  Pleva *et al*. in 2016          NA                    NA                          Moderate                                                    Low                                 Low                           Low

NA: Not applicable.

###### 

Assessment of observational studies

  Studies                           Selection   Comparability   Outcome   Total score
  --------------------------------- ----------- --------------- --------- -------------
  Almalla *et al*. in 2015          4           0               3         7
  Basavarajaiah *et al*. in 2015    4           0               2         6
  Kang *et al*. in 2015             4           0               3         7
  Kawamoto *et al*. in 2015         4           0               3         7
  Kubo *et al*. in 2015             4           0               3         7
  Lee *et al*. in 2017              4           0               3         7
  Marquis Gravel *et al*. in 2013   NA          NA              NA        NA
  Naganuma *et al*. in 2016         4           0               2         6

NA: Not applicable.

###### 

Funnel plot of target lesion revascularization. *RR*: Risk ratio; RCT: Randomized controlled trial.

###### 

Click here for additional data file.

Primary endpoint {#sec2-7}
----------------

Overall, 11 trials and 2 trials reported the incidence of TLR and TVR, respectively. As shown in \[[Figure 2](#F2){ref-type="fig"}\], the risk of TLR was comparable between the DEB group and the new-generation DES group (*RR* = 1.24, 95% *CI*: 0.89--1.72, *P* = 0.21, *I*^2^= 53%). In addition, no difference was found between the two groups in RCTs (*RR* = 1.36, 95% *CI*: 0.60--3.06, *P* = 0.46, *I*^2^= 61%) and in observational studies (*RR* = 1.19, 95% *CI*: 0.83--1.72, *P* = 0.35, *I*^2^= 53%).

![Forest plot of target lesion revascularization associated with drug-eluting balloon (DEB) versus new-generation drug-eluting stent (DES) for patients with in-stent restenosis. *CI*: Confidence interval.](CMJ-131-600-g002){#F2}

Secondary endpoints {#sec2-8}
-------------------

The all-cause death was reported in 10 trials. In general, DEB was associated with increased all-cause mortality (*RR* = 1.65, 95% *CI*: 1.09--2.50, *P* = 0.02, *I*^2^= 0%) compared with new-generation DES for the treatment of ISR. To be specific, the risk of all-cause mortality was different between the two treatment strategies only in the real-world observational studies (*RR* = 1.79, 95% *CI*: 1.12--2.88, *P* = 0.02, *I*^2^= 0%), whereas it was similar between the two treatment strategies in RCTs (*RR* = 1.24, 95% *CI*: 0.52--2.96, *P* = 0.63, *I*^2^= 0%; [Figure 3a](#F3){ref-type="fig"}).

![Forest plot of all-cause death (a), cardiac death (b), major adverse cardiovascular event (c), myocardial infarction (d), and stent thrombosis (e) associated with drug-eluting balloon (DEB) versus new-generation drug-eluting stent (DES) for patients with in-stent restenosis. *CI*: Confidence interval.](CMJ-131-600-g003){#F3}

The two treatment strategies were not significantly different in terms of other clinical outcomes including cardiac death (*RR* = 1.55, 95% *CI*: 0.89--2.71, *P* = 0.12, *I*^2^= 0%; [Figure 3b](#F3){ref-type="fig"}), MACE (*RR* = 1.21, 95% *CI*: 0.98--1.48, *P* = 0.07, *I*^2^= 22%; [Figure 3c](#F3){ref-type="fig"}), MI (*RR* = 1.12, 95% *CI*: 0.72--1.76, *P* = 0.62, *I*^2^= 0%; [Figure 3d](#F3){ref-type="fig"}), and ST (*RR* = 0.95, 95% *CI*: 0.38--2.42, *P* = 0.92, *I*^2^= 0%; [Figure 3e](#F3){ref-type="fig"}). Besides, the differences in these clinical outcomes were not significant between the two treatment strategies in RCTs or in observational studies.

The data about angiographic endpoints were reported in six studies. As shown in [Figure 4](#F4){ref-type="fig"}, patients treated with DEB obtained similar LLL to those treated with new-generation DES (*MD* = −0.05 mm, 95% *CI*: −0.24--−0.14 mm, *P* = 0.64, *I*^2^= 86%; [Figure 4a](#F4){ref-type="fig"}). However, DEB is associated with smaller MLD compared with new-generation DES (*MD*: −0.20 mm, 95% *CI*: −0.36--−0.04 mm, *P* = 0.01, *I*^2^= 76%; [Figure 4b](#F4){ref-type="fig"}).

![Forest plot of late lumen loss (a) and minimal lumen diameter (b) associated with drug-eluting balloon (DEB) versus new-generation drug-eluting stent (DES) for patients with in-stent restenosis. *CI*: Confidence interval.](CMJ-131-600-g004){#F4}

Sensitivity analysis {#sec2-9}
--------------------

Sensitivity analysis was performed by evaluating the influence of variables on the pooled estimates. Subsequently, it was found that results were similar to the overall analysis results \[[Table 2](#T5){ref-type="table"}\]. Furthermore, sensitivity analysis conducted through the removal of any single trial showed that it did not essentially affect the overall pooled estimate of TLR. Note, however, that the statistical difference in all-cause mortality between the DEB group and the new-generation DES group no longer existed after excluding the study by Lee *et al*.\[[@ref22]\] (*RR* = 1.48, 95% *CI*: 0.91--2.40) or Marquis-Gravel *et al*.\[[@ref23]\] (*RR* = 1.48, 95% *CI*: 0.93--2.37; data not shown).

###### 

Sensitivity analysis based on the influence of variables on the pooled estimates

  Endpoints       Overall               BMS ISR               DES ISR              SeQuent Please exclusively   EES exclusively       Excluding recurrent ISR
  --------------- --------------------- --------------------- -------------------- ---------------------------- --------------------- -------------------------
  TLR             1.24 (0.89, 1.72)     0.98 (0.22, 4.41)     1.16 (0.74, 1.84)    1.56 (0.84, 2.87)            1.36 (0.67, 2.76)     1.14 (0.80, 1.61)
  Death           1.65 (1.09, 2.50)     2.15 (0.64, 7.19)     1.02 (0.48, 2.16)    1.28 (0.60, 2.72)            1.23 (0.68, 2.24)     1.71 (1.10, 2.66)
  Cardiac death   1.55 (0.89, 2.71)     1.78 (0.37, 8.48)     1.21 (0.47, 3.13)    1.25 (0.46, 3.37)            1.12 (0.45, 2.83)     1.56 (0.88, 2.76)
  MACE            1.21 (0.98, 1.48)     0.81 (0.37, 1.79)     1.15 (0.87, 1.52)    1.18 (0.81, 1.73)            1.04 (0.69, 1.56)     1.21 (0.96, 1.51)
  MI              1.12 (0.72, 1.76)     0.74 (0.25, 2.22)     1.95 (0.82, 4.62)    1.07 (0.51, 2.21)            1.09 (0.56, 2.12)     1.04 (0.66, 1.66)
  ST              0.95 (0.38, 2.42)     1.44 (0.23, 9.01)     0.60 (0.08, 4.83)    1.88 (0.38, 9.20)            1.30 (0.31, 5.36)     0.78 (0.25, 2.39)
  LLL             −0.05 (−0.24, 0.14)   −0.06 (−0.36, 0.24)   0.12 (−0.02, 0.26)   −0.05 (−0.24, 0.14)          −0.05 (−0.24, 0.14)   −0.07 (−0.28, 0.14)

BMS: Bare-metal stent; DES: Drug-eluting stent; EES: Everolimus-eluting stent; ISR: In-stent restenosis; LLL: Late lumen loss; MACE: Major adverse cardiac events; MI: Myocardial infarction; ST: Stent thrombosis; TLR: Target lesion revascularization.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

This meta-analysis showed that although associated with smaller MLD, DEB was comparable to new-generation DES in the treatment of ISR in terms of TLR, cardiac death, MACE, MI, ST, and LLL. In addition, no significant difference in clinical outcomes was found between the DEB group and the new-generation DES group in RCTs. However, the use of DEB might increase the risk of all-cause mortality in observational studies.

Local drug delivery by DEB enables an immediate and homogenous drug uptake without stent struts or polymers.\[[@ref5][@ref28]\] Furthermore, it complements the normal vessel anatomy by avoiding inflammatory reactions. Compared with DES, it avoids multiple stent strut layers in ISR lesions, thereby shortening the duration of dual antiplatelet therapy. In fact, previous studies have demonstrated the benefits of DEB in the treatment of BMS ISR and DES ISR.\[[@ref6]\] Compared with plain balloon angioplasty, DEB is more effective in treating coronary ISR with long-term clinical benefits of up to 5 years.\[[@ref29]\] Recently, similar results of using DEB and the first-generation DES have been reported in the treatment of ISR.\[[@ref2]\] Accordingly, updated ESC guidelines have suggested that DEB can be used in patients with ISR (class of recommendation I, level of evidence A).\[[@ref6]\]

New-generation DES, especially EES, is the most common type of DES used in the current interventional practice.\[[@ref30][@ref31]\] EES made of cobalt-chromium or platinum-chromium alloys has a thinner strut than first-generation DES and it also uses a biocompatible fluoropolymer while the paclitaxel-eluting stent uses a durable polymer, which is associated with medial necrosis, positive remodeling, and excessive fibrin deposition.\[[@ref32]\] Previous meta-analysis has shown that the new-generation DES, such as EES or zotarolimus-eluting stent, has improved safety and efficacy than the first-generation DES.\[[@ref7]\] To date, however, there are few RCTs involving the comparison of DEB with the new-generation DES. The RIBS IV trial has reported that cobalt-chromium EES enables better clinical and angiographic results than SeQuent Please in 1 year.\[[@ref15]\] Nevertheless, the DARE trial presented at TCT conference has shown that MLD in the SeQuent Please group is noninferior to that in the platinum-chromium EES group (1.71 ± 0.51 mm vs. 1.74 ± 0.61 mm, *P*~noninferiority~\< 0.0001). Furthermore, SeQuent Please is associated with less LLL than platinum-chromium EES (0.17 ± 0.41 mm vs. 0.45 ± 0.47 mm, *P* \< 0.001), while the combined clinical outcome measure (10.9% vs. 9.2%, *P* = 0.66) and the need for TVR (8.8% vs. 7.1%, *P* = 0.65) are similar between the two treatment strategies.\[[@ref9]\] In this context, we performed this meta-analysis to evaluate the relative safety and efficacy of DEB to those of the new-generation DES.

Liou *et al*.\[[@ref8]\] found that DEB tends to be associated with increased risk of TLR and MACE, but their study was limited by small sample size. Our meta-analysis of all the available trials indicated that the risk of TLR and MACE was similar between the DEB group and the new-generation DES group, especially in RCTs. This meant the superior angiographic outcome did not indicate significantly enhanced clinical outcomes, even though MLD was significantly smaller in the DEB group than in the new-generation DES group. Nevertheless, all-cause mortality was significantly higher in the DEB group in the real-world observational studies, where selection bias could not be avoided. In clinical scenarios, DEBs are more likely to be applied when patients are presented with complex lesions, recurrent restenosis, or co-morbidities hampering prolonged dual antiplatelet therapy. Notably, the incidence of all-cause death is not significantly different between the DEB group and the new-generation DES group in the RCTs.

Nowadays, EES is the most extensively applied new-generation DES, which has shown improved safety and efficacy than the first-generation DES.\[[@ref7]\] Nonetheless, analysis restricted to EES alone has demonstrated that EES is not superior to DEB in terms of primary and secondary endpoints. SeQuent Please, which is also widely employed, enables the complete release of paclitaxel after the first balloon expansion on the target site with higher bioavailability than DIOR.\[[@ref33][@ref34]\] In this setting, the studies adopted SeQuent Please were reanalyzed exclusively. Fortunately, the analysis results show that SeQuent Please gives similar angiographic and clinical results to the new-generation DES.

Our meta-analysis presented several limitations that could not be ignored. First, this meta-analysis included both RCTs and observational studies, and the randomized data were limited. Notably, baseline differences originated from the nonrandomized real-world studies might affect the results. Second, consistent heterogeneity was observed for the TLR. Stratified analysis limited to more homogeneous subgroups of patients was performed and random effects model was used to account for the heterogeneity. Third, different types of new-generation DES in the various trials were an important source of heterogeneity. Fourth, there was a certain relevant heterogeneity with regard to the various DEBs although all the DEBs adopted were paclitaxel-coated balloons. To mitigate heterogeneity, analysis of SeQuent Please was conducted exclusively. Fifth, two studies with recurrent ISR were incorporated because studies comparing DEB and new-generation DES were limited. Fortunately, sensitivity analysis performed by excluding the two studies demonstrated that the results were mostly similar to the results of the overall analysis.

In conclusion, this meta-analysis showed that DEB and new-generation DES had comparable safety and efficacy for the treatment of ISR in RCTs. However, treatment with DEB was associated with higher risk of all-cause mortality in real-world nonrandomized studies. Further, large-scale and well-designed RCTs are expected to clarify the safety and efficacy of DEB and new-generation DES in ISR therapy.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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